Literature DB >> 29894692

Liver Cancer Initiation Requires p53 Inhibition by CD44-Enhanced Growth Factor Signaling.

Debanjan Dhar1, Laura Antonucci1, Hayato Nakagawa2, Ju Youn Kim1, Elisabeth Glitzner3, Stefano Caruso4, Shabnam Shalapour1, Ling Yang5, Mark A Valasek6, Sooyeon Lee7, Kerstin Minnich8, Ekihiro Seki9, Jan Tuckermann10, Maria Sibilia3, Jessica Zucman-Rossi4, Michael Karin11.   

Abstract

How fully differentiated cells that experience carcinogenic insults become proliferative cancer progenitors that acquire multiple initiating mutations is not clear. This question is of particular relevance to hepatocellular carcinoma (HCC), which arises from differentiated hepatocytes. Here we show that one solution to this problem is provided by CD44, a hyaluronic acid receptor whose expression is rapidly induced in carcinogen-exposed hepatocytes in a STAT3-dependent manner. Once expressed, CD44 potentiates AKT activation to induce the phosphorylation and nuclear translocation of Mdm2, which terminates the p53 genomic surveillance response. This allows DNA-damaged hepatocytes to escape p53-induced death and senescence and respond to proliferative signals that promote fixation of mutations and their transmission to daughter cells that go on to become HCC progenitors.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CD44; DNA damage response; EGFR; HCC; MDM2 nuclear translocation; cancer initiation; hepatocellular carcinoma; liver cancer; p53; p53 termination

Mesh:

Substances:

Year:  2018        PMID: 29894692      PMCID: PMC6005359          DOI: 10.1016/j.ccell.2018.05.003

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  64 in total

1.  Ras, protein kinase C zeta, and I kappa B kinases 1 and 2 are downstream effectors of CD44 during the activation of NF-kappa B by hyaluronic acid fragments in T-24 carcinoma cells.

Authors:  K A Fitzgerald; A G Bowie; B S Skeffington; L A O'Neill
Journal:  J Immunol       Date:  2000-02-15       Impact factor: 5.422

2.  TAK1 suppresses a NEMO-dependent but NF-kappaB-independent pathway to liver cancer.

Authors:  Kira Bettermann; Mihael Vucur; Johannes Haybaeck; Christiane Koppe; Jörn Janssen; Felix Heymann; Achim Weber; Ralf Weiskirchen; Christian Liedtke; Nikolaus Gassler; Michael Müller; Rita de Vos; Monika Julia Wolf; Yannick Boege; Gitta Maria Seleznik; Nicolas Zeller; Daniel Erny; Thomas Fuchs; Stefan Zoller; Stefano Cairo; Marie-Annick Buendia; Marco Prinz; Shizuo Akira; Frank Tacke; Mathias Heikenwalder; Christian Trautwein; Tom Luedde
Journal:  Cancer Cell       Date:  2010-05-18       Impact factor: 31.743

3.  TAK1-mediated autophagy and fatty acid oxidation prevent hepatosteatosis and tumorigenesis.

Authors:  Sayaka Inokuchi-Shimizu; Eek Joong Park; Yoon Seok Roh; Ling Yang; Bi Zhang; Jingyi Song; Shuang Liang; Michael Pimienta; Koji Taniguchi; Xuefeng Wu; Kinji Asahina; William Lagakos; Mason R Mackey; Shizuo Akira; Mark H Ellisman; Dorothy D Sears; Jerrold M Olefsky; Michael Karin; David A Brenner; Ekihiro Seki
Journal:  J Clin Invest       Date:  2014-07-01       Impact factor: 14.808

4.  HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation.

Authors:  B P Zhou; Y Liao; W Xia; Y Zou; B Spohn; M C Hung
Journal:  Nat Cell Biol       Date:  2001-11       Impact factor: 28.824

5.  Hepatocyte transplantation into diseased mouse liver. Kinetics of parenchymal repopulation and identification of the proliferative capacity of tetraploid and octaploid hepatocytes.

Authors:  T C Weglarz; J L Degen; E P Sandgren
Journal:  Am J Pathol       Date:  2000-12       Impact factor: 4.307

6.  The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors.

Authors:  Michael Hedvat; Dennis Huszar; Andreas Herrmann; Joseph M Gozgit; Anne Schroeder; Adam Sheehy; Ralf Buettner; David Proia; Claudia M Kowolik; Hong Xin; Brian Armstrong; Geraldine Bebernitz; Shaobu Weng; Lin Wang; Minwei Ye; Kristen McEachern; Huawei Chen; Deborah Morosini; Kirsten Bell; Marat Alimzhanov; Stephanos Ioannidis; Patricia McCoon; Zhu A Cao; Hua Yu; Richard Jove; Michael Zinda
Journal:  Cancer Cell       Date:  2009-12-08       Impact factor: 31.743

7.  Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair.

Authors:  Chang-Goo Huh; Valentina M Factor; Aránzazu Sánchez; Koichi Uchida; Elizabeth A Conner; Snorri S Thorgeirsson
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-30       Impact factor: 11.205

8.  Hepatocyte necrosis induced by oxidative stress and IL-1 alpha release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis.

Authors:  Toshiharu Sakurai; Guobin He; Atsushi Matsuzawa; Guann-Yi Yu; Shin Maeda; Gary Hardiman; Michael Karin
Journal:  Cancer Cell       Date:  2008-08-12       Impact factor: 31.743

9.  Targeted in vivo expression of the cyclin-dependent kinase inhibitor p21 halts hepatocyte cell-cycle progression, postnatal liver development and regeneration.

Authors:  H Wu; M Wade; L Krall; J Grisham; Y Xiong; T Van Dyke
Journal:  Genes Dev       Date:  1996-02-01       Impact factor: 11.361

10.  Genomic profiling of hepatocellular adenomas reveals recurrent FRK-activating mutations and the mechanisms of malignant transformation.

Authors:  Camilla Pilati; Eric Letouzé; Jean-Charles Nault; Sandrine Imbeaud; Anaïs Boulai; Julien Calderaro; Karine Poussin; Andrea Franconi; Gabrielle Couchy; Guillaume Morcrette; Maxime Mallet; Saïd Taouji; Charles Balabaud; Benoit Terris; Frédéric Canal; Valérie Paradis; Jean-Yves Scoazec; Anne de Muret; Catherine Guettier; Paulette Bioulac-Sage; Eric Chevet; Fabien Calvo; Jessica Zucman-Rossi
Journal:  Cancer Cell       Date:  2014-04-14       Impact factor: 31.743

View more
  68 in total

1.  The Molecular Chaperone Heat Shock Protein 70 Controls Liver Cancer Initiation and Progression by Regulating Adaptive DNA Damage and Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Signaling Pathways.

Authors:  Wonkyoung Cho; Xiongjie Jin; Junfeng Pang; Yan Wang; Nahid F Mivechi; Demetrius Moskophidis
Journal:  Mol Cell Biol       Date:  2019-04-16       Impact factor: 4.272

Review 2.  The role of MDM2-p53 axis dysfunction in the hepatocellular carcinoma transformation.

Authors:  Hui Cao; Xiaosong Chen; Zhijun Wang; Lei Wang; Qiang Xia; Wei Zhang
Journal:  Cell Death Discov       Date:  2020-06-19

3.  miR-552 promotes laryngocarcinoma cells proliferation and metastasis by targeting p53 pathway.

Authors:  Jia Gu; Tao Han; Lei Sun; Ai-Hui Yan; Xue-Jun Jiang
Journal:  Cell Cycle       Date:  2020-04-01       Impact factor: 4.534

4.  Dietary Additives and Supplements Revisited: The Fewer, the Safer for Liver and Gut Health.

Authors:  Rachel Golonka; Beng San Yeoh; Matam Vijay-Kumar
Journal:  Curr Pharmacol Rep       Date:  2019-06-10

5.  Circular RNA cia-MAF drives self-renewal and metastasis of liver tumor-initiating cells via transcription factor MAFF.

Authors:  Zhenzhen Chen; Tiankun Lu; Lan Huang; Zhiwei Wang; Zhongyi Yan; Yubo Guan; Wenjing Hu; Zusen Fan; Pingping Zhu
Journal:  J Clin Invest       Date:  2021-10-01       Impact factor: 14.808

6.  The Effect of Encapsulated Apigenin Nanoparticles on HePG-2 Cells through Regulation of P53.

Authors:  Mayada Mohamed Mabrouk Zayed; Heba A Sahyon; Nemany A N Hanafy; Maged A El-Kemary
Journal:  Pharmaceutics       Date:  2022-05-29       Impact factor: 6.525

7.  Mouse Homolog of the Human TP53 R337H Mutation Reveals Its Role in Tumorigenesis.

Authors:  Ji-Hoon Park; Jie Li; Matthew F Starost; Chengyu Liu; Jie Zhuang; Jichun Chen; Maria I Achatz; Ju-Gyeong Kang; Ping-Yuan Wang; Sharon A Savage; Paul M Hwang
Journal:  Cancer Res       Date:  2018-07-24       Impact factor: 12.701

Review 8.  The immunological and metabolic landscape in primary and metastatic liver cancer.

Authors:  Xin Li; Pierluigi Ramadori; Dominik Pfister; Marco Seehawer; Lars Zender; Mathias Heikenwalder
Journal:  Nat Rev Cancer       Date:  2021-07-29       Impact factor: 60.716

9.  Novel CDK9 inhibitor oroxylin A promotes wild-type P53 stability and prevents hepatocellular carcinoma progression by disrupting both MDM2 and SIRT1 signaling.

Authors:  Jing-Yue Yao; Shu Xu; Yue-Ning Sun; Ye Xu; Qing-Long Guo; Li-Bin Wei
Journal:  Acta Pharmacol Sin       Date:  2021-06-29       Impact factor: 6.150

10.  Functional Genomic Screening During Somatic Cell Reprogramming Identifies DKK3 as a Roadblock of Organ Regeneration.

Authors:  Frank Arnold; Pallavi U Mahaddalkar; Johann M Kraus; Xiaowei Zhong; Wendy Bergmann; Dharini Srinivasan; Johann Gout; Elodie Roger; Alica K Beutel; Eugen Zizer; Umesh Tharehalli; Nora Daiss; Ronan Russell; Lukas Perkhofer; Rupert Oellinger; Qiong Lin; Ninel Azoitei; Frank-Ulrich Weiss; Markus M Lerch; Stefan Liebau; Sarah-Fee Katz; André Lechel; Roland Rad; Thomas Seufferlein; Hans A Kestler; Michael Ott; Amar Deep Sharma; Patrick C Hermann; Alexander Kleger
Journal:  Adv Sci (Weinh)       Date:  2021-05-13       Impact factor: 16.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.